

Director/PDMR Shareholding

March 28, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)

Notification of transactions by person discharging managerial responsibilities

1.	Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”)		
a)	Name	Philip Vickers	
2.	Reason for the notification		
a)	Position / status	Head of Research and Development – PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor		
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares (“ADSs”)	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Disposal of ADSs	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$177.59	100
		\$177.59	100
		\$177.58	100
		\$177.58	100
		\$177.57	100
		\$177.56	100
		\$177.55	100
		\$177.51	10
		\$177.49	100
		\$177.47	100
		\$177.47	100
		\$177.48	100

		\$177.44	204
		\$177.44	96
d)	Aggregated information	Weighted average price	Volume
	- Aggregated volume	\$177.52	1,410
	- Price		
e)	Date of the transaction	March 27, 2017	
f)	Place of the transaction	NASDAQ	
5.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares (“ADSs”)	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Disposal of ADSs	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$177.50	200
		\$177.44	400
		\$177.45	200
		\$177.44	1
		\$177.45	600
		\$177.45	300
d)	Aggregated information	Weighted average price	Volume
	- Aggregated volume	\$177.45	1,701
	- Price		
e)	Date of the transaction	March 27, 2017	
f)	Place of the transaction	NYSE BEST	

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations

Ian Karp

ikarp@shire.com

+1 781 482 9018

Robert Coates

rcoates@shire.com

+44 1256 894874

Media

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Debbi Ford

debbi.ford@shire.com

+1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com